+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06313437

Phase I Study of Revumenib Combined With 73 Chemotherapy and Midostaurin for Newly Diagnosed NPM1 and FLT3 Mutated Acute Myeloid Leukemia

Led by Richard Stone, MD · Updated on 2026-03-25

22

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new combination treatment for adults aged 18 to 75 with newly diagnosed Acute Myeloid Leukemia AML that has specific gene mutations NPM1 and FLT3. This phase I trial aims to find the safest and most effective dose of revumenib, a menin inhibitor, when given with standard chemotherapy drugs cytarabine and daunorubicin 73 regimen plus midostaurin, a FLT3-targeted therapy. The Food and Drug Administration FDA has not approved this drug combination for AML treatment yet. Participants receive treatment in cycles lasting 28 days. During the induction cycle, they take daunorubicin for 3 days, cytarabine for 7 days, midostaurin twice daily from days 8 to 21, and revumenib twice daily from days 8 to 28. If needed, participants may have a reinduction cycle with similar timing but shorter cytarabine exposure, followed by a consolidation cycle where cytarabine is given on days 1, 3, and 5 along with midostaurin and revumenib. All therapy is administered in the hospital, and dosing follows a standard 33 design to determine the recommended phase II dose. During the study, participants undergo screening and regular assessments including blood and urine tests, bone marrow biopsies, and heart monitoring with electrocardiograms ECGs. They continue treatment as long as side effects are manageable and the leukemia does not worsen. Researchers measure important outcomes such as dose-limiting toxicities, remission rates, measurable residual disease, and survival at one year. Follow-up visits occur after each treatment cycle to monitor health and response.

CONDITIONS

Brief Title

Revumenib in Combination With 7+3 + Midostaurin in AML

Research Team

R

Richard Stone, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here